Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.65 |
| ▸ | TYR | P14679 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3483605 | 1.00 | CHRNA7 (0.65) | CHRNA7TYRPKMPTPN1HSD17B1 | |
| SCHEMBL3483887 | 0.92 | CHRNA7 (0.63) | CHRNA7TYRPTPN1HSD17B2KMT2A | |
| SCHEMBL3483889 | 0.92 | CHRNA7 (0.63) | CHRNA7TYRPTPN1HSD17B2KMT2A | |
| SCHEMBL3483624 | 0.91 | PKM (0.53) | CHRNA7TYRPKMPTPN1HSD17B1 | |
| SCHEMBL3483857 | 0.91 | PKM (0.53) | CHRNA7TYRPKMPTPN1HSD17B1 | |
| SCHEMBL3483621 | 0.91 | PKM (0.53) | CHRNA7TYRPKMPTPN1HSD17B1 | |
| SCHEMBL3483860 | 0.91 | PKM (0.53) | CHRNA7TYRPKMPTPN1HSD17B1 | |
| SCHEMBL3484373 | 0.90 | CHRNA7 (0.60) | CHRNA7TYRKMT2A | |
| SCHEMBL3484371 | 0.90 | CHRNA7 (0.60) | CHRNA7TYRKMT2A | |
| SCHEMBL3483869 | 0.88 | PKM (0.52) | CHRNA7PKMPTPN1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601943-B1 | Anti-cancer composition containing chalcone compounds | SEOUL NAT UNIV IND FOUNDATION (KR) | 2015-07-22 | — | — | EP | claimed |
| US-20130178533-A1 | COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE | SNU R&DB FOUNDATION (KR) | 2013-07-11 | — | — | US | claimed |
| EP-2601943-A1 | Anti-cancer composition containing chalcone compounds | Seoul National University Industry Foundation (KR) | 2013-06-12 | — | — | EP | claimed |
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2010-03-18 | — | — | US | claimed |
| EP-2601943-B1 | Anti-cancer composition containing chalcone compounds | SEOUL NAT UNIV IND FOUNDATION (KR) | 2015-07-22 | — | — | EP | disclosed |
| US-9072698-B2 | Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2015-07-07 | — | — | US | disclosed |
| US-9057725-B2 | Composition for diagnosing, treating, and preventing liver disease | SNU R&DB FOUNDATION (KR) | 2015-06-16 | — | — | US | disclosed |
| US-20130178533-A1 | COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE | SNU R&DB FOUNDATION (KR) | 2013-07-11 | — | — | US | disclosed |
| EP-2601943-A1 | Anti-cancer composition containing chalcone compounds | Seoul National University Industry Foundation (KR) | 2013-06-12 | — | — | EP | disclosed |
| US-8445722-B2 | Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) | 2013-05-21 | — | — | US | disclosed |
| EP-2099440-B1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 | SEOUL NAT UNIV IND FOUNDATION (KR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120282619-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY | 2012-11-08 | — | — | US | disclosed |
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | TM9SF4, TM9SF2, TM9SF3 | CHRNA7 4573/4885TYR 3484/4885PKM 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.